clinical trial · NCT06928389
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Akeso·phase3·recruiting·n = 536
Non-Small Cell Lung CancerIvonescimab, docetaxelPlacebo, docetaxel
brief summary
This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.
started
Jul 8, 2025
primary completion
May 1, 2027
completion
Jun 1, 2030
last updated
Apr 9, 2026
official title
A Randomized, Double-blind, Multicenter Phase 3 Clinical Trial of Ivonescimab Versus Placebo, Combined With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) That Has Progressed on or After PD-(L)1 Inhibitor-based Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol